K-number	K141771
Device name	PROSIGNA BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Applicant	Nanostring Technologies, Inc.
Product code	NYI
Device class	Class II
Decision date	Nov 7, 2014
Decision	Substantially Equivalent
Regulation	866.6040

AI Summary

AI extraction for this record is queued and will appear within 24 hours. View full FDA record →

Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?

Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.

Start free trial →

Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →

PROSIGNA BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Everything you need for a 510(k) submission. Nothing you don't.